SUMMARY
INTRODUCTION
Introduction of the lentiviral vector (LV) platform has spurred applications of gene therapy based on the transplantation of ex-vivo-engineered, autologous hematopoietic stem and progenitor cells (HSPCs) (Naldini, 2015) . Recent clinical trials for patients affected by primary immunodeficiencies, hemoglobinopathies, or inborn errors of metabolism have shown high levels of gene transfer into HSPCs, which were stably maintained in multiple hematopoietic lineages until the latest follow-up, reaching up to 9 years in the earliest trial (Cartier et al., 2009; Aiuti et al., 2013; Biffi et al., 2013; Hacein-Bey Abina et al., 2015; Sessa et al., 2016) . The post-transplant hematopoiesis reconstituted by polyclonal, gene-marked HSPCs has provided substantial and sustained therapeutic benefit to most treated patients to date. Contrary to the gene therapy trials performed with gamma-retroviral vectors, no adverse events related to insertional mutagenesis of semi-randomly integrating LVs have been reported to date, even though substantial integration loads, typically ranging over 5-20 million integrations per kg body weight, have now been infused into >150 patients. The side effects reported in these gene therapy trials are typically related to the conditioning regimen and include mucositis and temporary bone marrow (BM) aplasia. Trials employing full myeloablation and BM-derived transduced CD34 + cells often showed more prolonged grade 4 neutropenia and thrombocytopenia than allogeneic BM transplantation, despite administering at least similar doses of CD34 + cells/kg (Sessa et al., 2016) . Delayed recovery may be caused by the ex vivo culture of the cell therapy product, which typically lasts more than 60 hr (Aiuti et al., 2013; Biffi et al., 2013) . Indeed, experimental evidence has accumulated that cultured HSPCs progressively lose engraftment potential by recruitment into cell cycle and loss of adhesion molecules, thus impeding their homing into the niche and driving lineage commitment and differentiation (Glimm et al., 2000; Kallinikou et al., 2012; Larochelle et al., 2012) . This notion contrasts with recent reports on successful ex vivo cord blood (CB) expansion leading to accelerated hematologic recovery in patients (reviewed in Kiernan et al., 2016) . Differences among HSPC sources (CB versus BM or mobilized peripheral blood [mPB] ) may contribute to diverging outcomes, and a complete understanding is key to harnessing emerging CB expansion protocols for ex vivo gene transfer procedures, which utilize BM or mPB HSPCs. Moreover, CD34 + HSPCs comprise a heterogeneous mixture of progenitors at various stages of lineage commitment, the composition of which changes according to age, cell source, and mobilization procedure, and studies investigating the impact of ex vivo culture on defined subpopulations are lacking. Only a minute fraction of these CD34 + cells corresponds to long-term (LT) hematopoietic stem cells (HSCs). Limiting-dilution transplants into immunodeficient mice indicate that no more than 0.1% of lineage-negative CB cells (50%-75% CD34 + ) engraft longterm (McDermott et al., 2010) . from patients treated by gene therapy indicate that $0.01% of the infused CD34 + cells contribute to long-term hematopoiesis (Aiuti et al., 2013; Biffi et al., 2013; Biasco et al., 2015) . These data indicate that there is a substantial margin to more precisely tailor gene transfer to LT-HSCs as opposed to the bulk of CD34 + cells, adapting ex vivo manipulation specifically to the requirements of the therapeutically relevant cell subsets. Several landmark studies have identified surface markers that allow prospective isolation of functionally diverse HSPC subsets (Majeti et al., 2007; Notta et al., 2011 Here we undertake a comprehensive strategy to advance ex vivo genetic engineering of HSPCs for gene therapy. We experimentally define an optimal, clinically applicable strategy to purify HSCs, which allows uncoupling longterm from short-term hematopoietic reconstitution, and implement ex vivo conditions that best preserve their biological properties applying transduction-enhancing compounds and pyrimidoindole derivatives to support ex vivo HSC expansion. Figure 2C ) and GFP + cell chimerism in the re-assembled graft stabilized around 50% in all lineages except T cells, where the CD34 prog contribution was higher ( Figure 2D ).
RESULTS

Definition of Functionally
This result is in contrast to the experiments described in Figure 1 , where similar sorting gates and transduction conditions have been used, except for the transplantation of cultured versus uncultured CD34 prog cells.
These data suggest that fresh CD34 prog cells (likely, within the CD38 low cell fraction) contain some longterm repopulating capacity, which is lost during 2 days of ex vivo culture. To directly test this hypothesis, we xenotransplanted mPB CD34 prog cells (the same donor and sorted aliquot as in the experiment shown in Figures 2B-2D) that were either uncultured, or cultured and transduced with a GFP LV during a 24 hr or a 48 hr ex vivo protocol. While engraftment at 3 weeks was similar or slightly better for the cultured cells, the 46 hr ex vivo group showed no short-or long-term engraftment thereafter, at variance to the uncultured group ( Figure 2E ). Interestingly, the shorter 24 hr ex vivo culture time restored engraftment potential to similar levels seen in uncultured cells. We repeated the experiment with CD38 prog cells from a different donor, confirming that short-term engraftment potential starts to decrease after 36 hr of culture ( Figure 2E ). These findings provide a strong rationale to reduce ex vivo culture times to improve progenitor cell potency in gene therapy products. + cells were transduced with LVs in the presence or absence of 10 mM PGE 2 . VCN was measured in the progeny after >7 days culture (n = 5) or in the human CD45 + cell xenograft harvested from the PB (n = 2 experiments, blood from individual mice was pooled) or BM (2 experiments, n = 13 mice in the no PGE 2 group, n = 10 mice in PGE 2 group, statistics by Student's t test).
(legend continued on next page)
We thus reasoned that CD34 stem HSPCs might better compete with uncultured progenitor cells when their ex vivo culture is reduced to 24 hr. In addition, we eliminated interleukin-3 (IL-3) from the culture medium, given that it stimulates progenitors rather than HSCs and has recently been implicated in accelerated loss of short-term repopulation potential (Miller et al., 2016 Figure 2F ). Importantly, up to 80% and 70% of hematopoietic progeny were stably gene marked in vivo, respectively, and equilibrium was reached between 3 and 4 months post-transplantation ( Figure 2G To date, most clinical protocols employ culture times of more than 60 hr and multiple exposures to LV (in general, two transduction cycles). Therefore, a significant challenge when implementing shorter transduction protocols in the clinic is to achieve sufficiently high levels of gene transfer with large-scale LV preparations produced under good manufacturing practice (GMP). Unexpectedly, we found that the more primitive CD34 + CD38 À cells were transduced to almost 2-fold-higher vector copy number per genome (VCN) than the more committed counterparts after a single LV exposure ( Figure S4 ). This phenomenon may facilitate gene transfer when manipulating more purified HSC populations. Furthermore, we sought to enhance transduction by small-molecule compounds. While employing 16,16-dimethyl prostaglandin E 2 (PGE 2 ) as an anti-apoptotic agent in ex vivo HSC gene-editing protocols, we noted that it increased gene-targeting efficiency (Genovese et al., 2014) . We hypothesized that PGE 2 may also increase transduction by integrating LV. Indeed, pre-stimulating CB CD34 + HSPCs with 10 mM PGE 2 before transduction increased VCN in the progeny $1.5-fold in vitro, an increase that was maintained or increased after xenotransplantation ( Figure 3A) . PGE 2 also enhanced transduction of CD34 + cells from BM ( Figure 3B ), including the more primitive CD34 + CD38 À subset, and mPB, whereby the (B) BM CD34 + subpopulations (n = 3 donors) were transduced with GFP LV (MOI = 100) + 10 mM PGE 2 or DMSO, and VCN was measured in the myeloid progeny after 14 days of culture or on myelo-erythroid colonies obtained from clonogenic assay. Statistics by two-way ANOVA with Bonferroni's multiple comparison test. (C) mPB CD34 + cells (n = 8 donors) were transduced with GFP LV (38 hr protocol) ± 10 mM PGE 2 added at the beginning of culture (t0) or during pre-stimulation, 120 min before LV addition (À120 0 ). Transduction was evaluated after 14 days in culture. Left: VCN relative to the no PGE 2 group (statistics by Wilcoxon signed rank test). Right: transduction efficiency measured by flow cytometry (n = 6) (statistics by Student's t test). (D) mPB CD34 + cells (n = 3 donors, with two replicates each) were transduced with GFP-expressing LV variants after adding PGE 2 or DMSO (À120 0 ). IDLV, integrase-deficient, VSV-G pseudotyped LV; VSV LV, integration-competent, VSV-G-pseudotyped LV; P90A and N74D, VSV-G-pseudotyped LV with capsid mutants; BaEV-TR and RD114-TR, integration-competent LV pseudotyped with the BaEV-TR and RD114-TR envelopes, respectively. VCN were measured by specific droplet digital PCR assays. Statistics were performed by Mann-Whitney test. (E) Quantification of late reverse-transcription DNA intermediates (late-RT) in mPB CD34 + cells (n = 6 donors), 6 hr after transduction (TD) in PGE 2 or DMSO. (F-H) mPB CD34 + cells were transduced with gp91 phox -expressing LVs (MOI = 100) using a 24 or 46 hr ex vivo protocol ± 10 mM PGE 2 , and xenotransplanted with the day 0 equivalent of 500,000 cells (n = 6-9 mice/group). + CD38 À cells were transduced with purified Globe LV (MOI = 100) using a 24 or 38 hr ex vivo protocol ±10 mM PGE 2 , and xenotransplanted with the day 0 equivalent of 50,000 cells (experiment 1: 38 hr no PGE 2 , n = 4; 38 hr + PGE 2 , n = 4; 24 hr + PGE 2 , n = 5; experiment 2: 38 hr no PGE 2 , n = 4; 38 hr + PGE 2 , n = 4; 24 hr no PGE 2 , n = 5; 24 hr + PGE 2 , n = 4). + HSPCs were expanded ex vivo in the presence of vehicle (DMSO) or StemRegenin 1 (SR1, 1 mM), as described by Boitano et al. (2010) Figure 3C ). At non-saturating LV doses, PGE 2 also increased the fraction of transduced cells, not only VCN ( Figure 3C ). We then tested whether PGE 2 increased transduction by vector variants to determine a mechanism of action. Gene transfer was increased when using vesicular stomatitis virus G protein (VSV-G)-pseudotyped, integrase-deficient LV, or gamma-retroviral vectors, and also in the case of HIV1 capsid mutants that reduce interaction with cyclophilin A (P90A) or CPSF6 (N74) during uncoating ( Figure 3D ). On the other hand, when pseudotyping LVs with alternative, non-endocytosis-dependent envelopes, we could not appreciate a significant impact of PGE 2 on transduction. Quantification of reversely transcribed vector DNA intermediates 6 hr post-transduction further indicated that PGE 2 acted during the early steps of transduction ( Figure 3E ). We then performed in vivo repopulation assays on CD34 + mPB cells transduced in the presence or absence of PGE 2 using either a 46 hr or an ultra-short 24 hr ex vivo culture protocol. Despite injecting fewer cells in the 24 hr protocol groups (the yield of 500,000 plated CD34 + cells was lower after 24 hr with respect to 46 hr, because of less proliferation during the shorter ex vivo culture), huCD45 + cell engraftment was equivalent to the 46 hr protocol ( Figure 3F ). PGE 2 treatment had no overall effect on ex vivo proliferation, colony-forming potential ( Figure S4D ), or engraftment levels ( Figure 3F ), nor did it alter the lineage composition of the human graft (Figure 3G ). At the experimental endpoint (20-24 weeks post-transplant), we noted significantly higher VCN in the PGE 2 groups ( Figure 3H showed that exposure to PGE 2 doubled VCN (Figure S4E ). Following transplantation, we detected no statistically significant differences in engraftment or graft composition ( Figures 3I and 3J) . Importantly, differences in VCN were maintained in the human graft at 18-20 weeks post-transplant, confirming that PGE 2 increased gene transfer into long-term repopulating cells ( Figure 3K ). Taken together, these results suggest that a minimal ex vivo manipulation protocol, as short as 24 hr, can achieve substantial levels of gene transfer by therapeutic LVs in human HSCs from clinically relevant sources. The effect of PGE 2 was particularly robust for the 38 hr protocol in CD34 + CD38
À cells, motivating its clinical implementation.
Ex Vivo Expansion of CD34 + CD38
À Cells from mPB in the Presence of Pyrimidoindole Derivatives Based on our finding that short-term engrafting cells are particularly sensitive to ex vivo culture, we hypothesized that HSC expansion protocols could be more suitably applied to highly purified HSC fractions. First, we set out to functionally validate surface markers that prospectively identify SRC after 1-2 weeks of expansion culture. BM or CB CD34 + cells were cultured in the presence or absence of the arylhydrocarbon receptor antagonist StemRegenin 1 (SR1) (Boitano et al., 2010) . Serial flow cytometric analysis indicated that CD38 expression was rapidly lost in culture, while a fraction of cells maintained a CD34 high CD90 + phenotype. This fraction was higher when cells were cultured with SR1, especially for CB ( Figure 4A ). À cells either after a minimal, 24-36 hr ex vivo culture (minimally manipulated cells) or after an additional 7-8 days of ex vivo expansion ( Figure 4E ). When matching transplanted cell number according to the same ''t0 equivalent'' (13 t0), we found higher engraftment in the ex vivo expanded sample ( Figure 4E , pink dots). When the transplanted cell dose was matched according to the postculture counts, ex vivo expanded cells showed lower engraftment compared with minimally manipulated cells, consistent with the 3-to 25-fold lower ''t0 equivalent'' cell dose (0.38-0.043 t0) injected ( Figure 4E , green dots).
To estimate the frequency of SRC in UM171-expanded CD34 + CD38 À HSPCs, we performed limiting-dilution statistics on the ''t0 equivalent'' cell doses that were transplanted in four replicate experiments ( Figure 4F ). Estimated SRC frequency was 1 in 10,700 (95% confidence interval: 5,500-21,100), which compares with a recently reported SRC frequency of $1 in 141,203 in uncultured CD34 + cells from G-CSF-mPB (Lidonnici et al., 2016) . Taken together, these data indicate that our protocol allows ex vivo expansion of genetically engineered mPB CD34 + CD38 À cells with SCID-repopulating potential and warrants further protocol optimization for clinical application.
DISCUSSION
Transplantation of genetically engineered, autologous HSPCs is emerging as a less risky and potentially more efficacious alternative to allogeneic transplantation for a series of non-malignant indications (Naldini, 2015) . To fully harness the advantages of gene therapy, genetic engineering of HSPCs must be developed into a standardized and sustainable method. To reach this objective, key challenges include improving LV transduction, minimizing the negative impact of ex vivo culture to ensure faster and more polyclonal long-term reconstitution, and alleviating the safety concerns related to insertional mutagenesis. Here we developed a series of readily translatable strategies that overcome these hurdles and help to establish gene therapy as a widely available standard treatment. We revealed the PGE 2 -enhanced transduction of human HSPCs by VSV-G-pseudotyped LV, possibly by acting on the endocytosis-dependent entry pathway. Applying PGE 2 makes shorter ex vivo manipulation protocols that feature a single transduction cycle clinically viable, mitigating the negative effect of prolonged culture on progenitor cell engraftment and allowing to double the number of patients that can be treated with a given vector batch with respect to current clinical standards. Importantly, the enhancing effect of PGE 2 on LV transduction has recently been reported by an independent group (Heffner et al., 2016) . In contrast to other pharmacological interventions that enhance transduction but may also have broader effects on HSC biology and/or cause toxicity (Wang et al., 2014; Petrillo et al., 2015) , PGE 2 was non-toxic, did not change the biological properties of the cells, and has already been safely employed in an ex vivo setting to increase CB engraftment in patients (Cutler et al., 2013) . We did not note a significant increase in engraftment levels in the PGE 2 groups, as could be expected from published data (Goessling et al., 2011) . Further studies on diverse cell sources employing ultra-short ex vivo protocols are warranted to understand whether the promoting effects of PGE 2 on LV transduction and engraftment capacity are functionally linked to a common mechanism and whether both effects can be exploited contemporaneously. The shortened PGE 2 protocol can be readily applied to current ex vivo gene therapy trials and should translate clinically into accelerated hematologic recovery.
We provide evidence here that CD34 + CD38 À cells transduce at higher levels than total CD34 + cells, consistent with a recent report (Baldwin et al., 2015) . In vitro, the effect was most robust (1) when cell populations were sorted before transduction ( Figure S4C ), (2) when saturating vector doses were used ( Figure S4B ), and (3) when PGE 2 was employed ( Figure 3B ). We hypothesize that the lack of cell division of CD34 + CD38 À cells during the first days of culture ( Figure 4F ) may give more time for infecting LV to complete integration before DNA replication, thus transmitting a copy of each provirus to both daughter cells, whereas the rapidly dividing CD38 + progenitors may randomly sort the LV pre-integration complexes between the two daughter cells. Considering that PGE 2 relieves an early transduction block, applying it to purified CD34 + CD38 À cells may provide added benefits in terms of gene transfer efficiency. Robust gene transfer into HSCs may allow reducing the intensity of the conditioning regimen and implementing non-genotoxic and stem cell-specific conditioning strategies (Palchaudhuri et al., 2016) . Regarding safety, avoiding the infusion of CD38 + progenitors carrying semi-random LV integrations would reduce the integration load 10-fold, thereby decreasing the chances of gain-of-function events due to insertional mutagenesis, which may originate from immortalized progenitor cells (Cavazzana-Calvo et al., 2010; Stein et al., 2010; Braun et al., 2014) . We argue that gene therapy based on transduced, purified CD34 + CD38 À cells is clinically feasible and offers advantages over alternative strategies that have previously been employed in clinical trials to obtain HSC-enriched cell populations, including positive selection for CD133 + cells (Gordon et al., 2003) or CD34 + CD90 + cells (Michallet et al., 2000; Negrin et al., 2000) . Combining a negative (CD38) with a positive (CD34) selection marker allows using a sequential, bead-based selection procedure that can be made GMP compliant and implemented in centers that already possess standard cell separation equipment. Our functional analyses showed that CD38 expression inversely correlated with time of onset and persistence of the graft, confirming and extending published results obtained in xenograft models (Glimm et al., 2001; Kerre et al., 2001; Mazurier et al., 2003 et al., 2007) . Unbalanced stimulation by high doses of cytokines may irreversibly push these cells to differentiate resulting in a loss of self-renewal potential and premature exhaustion in vivo. On the contrary, the more primitive CD34 + CD38 À mPB cells appeared to be more tolerant to ex vivo culture. Using the shortened transduction protocol, we effectively alleviated competition from a 10-fold excess of uncultured progenitors. Moreover, we demonstrate that, with the help of the pyrimidoindole derivative UM171 (Fares et al., 2014) , the culture time of mPB CD34 + CD38 À cells can extend beyond 7 days, with evidence for SRC expansion. We foresee numerous applications for ex vivo expansion of postnatally derived HSCs in the gene therapy field. This technology can overcome disease-or patient-specific cell shortages, allow more complex genetic manipulations such as serial transductions by multiple vectors, possibly with selection of engineered cells, and enable therapeutic application of emerging gene-editing technologies (Naldini, 2015) . The use of purified CD34 + CD38 À cells and the associated reduction in culture volumes and vector amount promises substantial cost savings and quality improvements, also considering that differentiating progenitor and mature cell populations may give rise to inhibitory feedback and differentiation signaling exhausting the long-term repopulating potential of the more primitive cells in the culture (Csaszar et al., 2012) .
In conclusion, our data support the stepwise introduction of incremental improvements in the ex vivo HSPC engineering process into clinical testing, ultimately fulfilling the promise of gene therapy to the community.
EXPERIMENTAL PROCEDURES
Mice NOD.Cg-Prkdc scid IL2rg tm1Wjl /SzJ (NSG) mice were acquired from the Jackson Laboratory. All animal procedures were performed according to protocols approved by the Institutional Animal Care and Use Committee (IACUC 618) and communicated to the Ministry of Health and local authorities according to the Italian law. Eight week old mice were sublethally irradiated (200-220 cGy) and transplanted with human HSPCs by tail vein injection. All mice were randomized into different HSC transplantation groups. On the basis of a standard backward sample size calculation, we transplanted at least three to ten mice per condition and performed at least two independent experiments to obtain a sufficient number of mice to perform statistical analysis. Human cell engraftment was blindly assessed by serial bleeding or BM aspirates, as described in the Supplemental Experimental Procedures.
Procurement, Culture, and Transduction of Human HSPCs
Human CB, BM, or mPB was purchased from commercial sources (Lonza, HemaCare, or All Cells). CD34 + or CD34 + CD38 À cells were pre-stimulated in serum-free medium supported with earlyacting human cytokines (SCF, FLT3L, or TPO with or without IL-3 or IL-6), and transduced with concentrated LV at an MOI of 100, unless otherwise indicated. Where indicated, 10 mM 16,16-dimethyl-prostaglandin E 2 (Cayman Chemical) was added before LV transduction. Additional details can be found in the Supplemental Experimental Procedures.
Cell Sorting and Flow Cytometry
Sorting for CD34 + cells (and CD38 À cells, where indicated) was performed by magnetic beads (Miltenyi). Fluorescence-activated cell sorting for CD38 and CD90 subpopulations was performed on a MoFlo XDP sorter (Beckman Coulter). Analytical flow cytometry was performed on a FACSCanto II or LSR II Fortessa instrument (BD Bioscience). Details on protocols and reagents can be found in the Supplemental Experimental Procedures.
Ex Vivo HSPC Expansion
Expansion cultures were set up in serum-free medium (StemSpan, STEMCELL Technologies or StemMacs, Miltenyi) containing, unless otherwise indicated, 100 ng/mL SCF, 100 ng/mL FLT3L, 50 ng/mL TPO, 50 ng/mL IL-6, 35 nM UM171 (STEMCELL Technologies), and/or 1 mM SR1 (BioVision Technologies). Starting cell density was 1 3 10 5 cells/mL, and fresh medium was manually added as needed, to keep cell concentration always below 1 3 10 6 cells/mL. Cultures were kept at 37 C, 5% CO 2 under normoxia.
LV Production, Titration, and Molecular Analysis of Gene Transfer Efficiency
Purified vectors (Globe LV, some batches of PGK.GFP LV) were produced and titered by MolMed, according to the GMP process employed in our clinical trials (Biffi et al., 2013; Aiuti et al., 2013) . Lab-grade vectors were produced and titered on 293T cells according to standard lab protocols, as described previously. Molecular quantification of gene transfer efficiency was performed using specific qPCR assays, as detailed in the Supplemental Experimental Procedures.
Statistical Analysis
In all studies, values are expressed as means ± SEM, unless otherwise indicated. Statistical analyses were performed by MannWhitney test, Student's t test, Wilcoxon signed rank test, or ANOVA test as indicated. Percentages were converted into log odds for statistical analysis. Significance levels are coded as follows throughout the manuscript: *p < 0.05, **p < 0.01, ***p < 0.001. 
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